Nifty
:
24888.20
Sensex
:
81691.98
-253.20 (-1.01%)
-823.16 (-1.00%)
Nifty
Sensex
:
:
24888.20
81691.98
-253.20 (-1.01%)
-823.16 (-1.00%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532523 | NSE: BIOCON

NSE BSE
352.25
12-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  355
  •  357.75
  •  349.5
  •  354.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4265927
  •  1510699211.6
  •  404.7
  •  291

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 42,309.14
  • 41.75
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,930.34
  • 0.14%
  • 1.95

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.46%
  • 13.63%
  • FII
  • DII
  • Others
  • 5.67%
  • 15.32%
  • 3.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.92
  • 18.55
  • 21.71

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.47
  • 20.52
  • 16.45

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.47
  • 5.64
  • 16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 58.40
  • 62.38
  • 50.48

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.66
  • 3.97
  • 2.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.62
  • 18.58
  • 13.49

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
8.55
8.46
6.37
11.76
P/E Ratio
41.20
41.64
55.30
29.95
Revenue
14756
15262
17551
20633
EBITDA
3215
4227
3887
4901
Net Income
1023
1013
764
1411
ROA
1.9
1.8
1.2
2.1
P/B Ratio
3.88
1.95
1.92
1.82
ROE
5.43
4.89
3.59
6.1
FCFF
571
1408
1525
2315
FCFF Yield
0.95
2.35
2.54
3.86
Net Debt
13702
13795
8342
7185
BVPS
90.89
180.28
183.36
193.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
4,417.00
3,917.10
12.76%
3,821.40
3,953.70
-3.35%
3,590.40
3,462.30
3.70%
3,432.90
3,422.60
0.30%
Expenses
3,338.80
3,001.20
11.25%
3,069.60
3,026.90
1.41%
2,905.00
2,720.70
6.77%
2,812.50
2,708.20
3.85%
EBITDA
1,078.20
915.90
17.72%
751.80
926.80
-18.88%
685.40
741.60
-7.58%
620.40
714.40
-13.16%
EBIDTM
24.41%
23.38%
19.67%
23.44%
19.09%
21.42%
18.07%
20.87%
Other Income
36.90
48.60
-24.07%
34.80
565.50
-93.85%
32.50
157.90
-79.42%
1,134.50
93.50
1,113.37%
Interest
212.40
227.00
-6.43%
223.40
266.70
-16.24%
225.60
247.70
-8.92%
236.00
233.00
1.29%
Depreciation
436.30
407.00
7.20%
425.40
414.50
2.63%
419.90
389.30
7.86%
405.40
358.00
13.24%
PBT
486.80
321.70
51.32%
155.90
832.30
-81.27%
98.40
238.50
-58.74%
1,145.50
216.90
428.12%
Tax
27.40
96.10
-71.49%
74.80
54.90
36.25%
71.30
41.60
71.39%
283.70
34.80
715.23%
PAT
459.40
225.60
103.63%
81.10
777.40
-89.57%
27.10
196.90
-86.24%
861.80
182.10
373.26%
PATM
10.40%
5.76%
2.12%
19.66%
0.75%
5.69%
25.10%
5.32%
EPS
2.87
1.13
153.98%
0.21
5.50
-96.18%
-0.13
1.05
-
5.49
0.84
553.57%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
Net Sales Growth
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
 
Cost Of Goods Sold
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
Gross Profit
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
GP Margin
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
Total Expenditure
12,125.90
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
Power & Fuel Cost
-
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
% Of Sales
-
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
Employee Cost
-
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
% Of Sales
-
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
Manufacturing Exp.
-
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
% Of Sales
-
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
General & Admin Exp.
-
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
% Of Sales
-
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
Selling & Distn. Exp.
-
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
% Of Sales
-
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
Miscellaneous Exp.
-
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
108.70
% Of Sales
-
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
EBITDA
3,135.80
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
EBITDA Margin
20.55%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
Other Income
1,238.70
967.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
Interest
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
Depreciation
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
PBT
1,886.60
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
Tax
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
Tax Rate
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
PAT
1,429.40
1,022.50
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
PAT before Minority Interest
1,013.30
1,297.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
Minority Interest
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
PAT Margin
9.37%
6.93%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
PAT Growth
3.43%
120.99%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
 
EPS
11.91
8.52
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
Share Capital
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
Total Reserves
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
Non-Current Liabilities
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
Secured Loans
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
Unsecured Loans
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
Long Term Provisions
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
Current Liabilities
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
Trade Payables
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
Other Current Liabilities
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
Short Term Borrowings
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
Short Term Provisions
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
Total Liabilities
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
Net Block
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
Gross Block
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
Accumulated Depreciation
7,287.40
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
Non Current Assets
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
Capital Work in Progress
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
Non Current Investment
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
Long Term Loans & Adv.
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
Other Non Current Assets
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
Current Assets
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
Current Investments
315.60
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
Inventories
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
Sundry Debtors
6,230.60
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
Cash & Bank
2,258.70
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
Other Current Assets
1,430.40
334.10
660.20
713.10
809.20
678.60
428.00
419.90
300.70
171.60
Short Term Loans & Adv.
1,096.00
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
Net Current Assets
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
Total Assets
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
PBT
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
Adjustment
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
Changes in Working Capital
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
Cash after chg. in Working capital
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
Net Fixed Assets
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
Net Investments
-47.80
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
Others
-633.50
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
Cash from Financing Activity
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
Net Cash Inflow / Outflow
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
Opening Cash & Equivalents
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
Closing Cash & Equivalent
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
ROA
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
ROE
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
ROCE
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
Fixed Asset Turnover
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
Receivable days
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
Inventory Days
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
Payable days
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
Cash Conversion Cycle
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
Total Debt/Equity
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
Interest Cover
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Biocon gets approval for diabetes drug Liraglutide in India
    3rd Jun 2025, 12:22 PM

    The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

    Read More
  • Biocon’s arm receives MHRA, UK approval for YESINTEK, Biosimilar Ustekinumab
    26th May 2025, 09:59 AM

    Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product

    Read More
  • Biocon reports two-fold jump in Q4 consolidated net profit
    9th May 2025, 14:41 PM

    The total consolidated income of the company increased by 12.31% at Rs 4,453.90 crore for Q4FY25

    Read More
  • Biocon’s arm secures multiple market access agreements for Yesintek
    5th May 2025, 09:28 AM

    The market access agreements from numerous plans represent over 100+ million lives in the United States

    Read More
  • Biocon gets nod to raise Rs 4,500 crore
    24th Apr 2025, 09:40 AM

    The Board of Directors at its meeting held on April 23, 2025, has inter-alia, considered and approved the same

    Read More
  • Biocon raises Rs 600 crore through commercial papers
    23rd Apr 2025, 10:28 AM

    Maturity of the said Commercial Papers will be on September 30, 2025

    Read More
  • Biocon's arm inks settlement and license agreement with Regeneron
    15th Apr 2025, 12:51 PM

    This agreement enables the company to launch ‘YESAFILI’ in the United States in the second half of calendar year 2026 or earlier in certain circumstances

    Read More
  • Biocon’s US arm recalling 2,184 bottles of medication to treat high cholesterol
    11th Apr 2025, 15:29 PM

    The company initiated the Class II recall on March 17, 2025

    Read More
  • Biocon’s arm gets USFDA’s nod for Everolimus Tablets
    11th Apr 2025, 10:22 AM

    The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products

    Read More
  • Biocon’s arm gets USFDA’s approval for Jobevne
    10th Apr 2025, 09:11 AM

    The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States

    Read More
  • Biocon gets nod to raise up to Rs 600 crore through commercial papers
    5th Apr 2025, 12:30 PM

    The Board of Directors at its meeting held on April 04, 2025, has approved the same

    Read More
  • Biocon’s arm gets USFDA’s nod for Norepinephrine Bitartrate Injection
    24th Mar 2025, 11:55 AM

    The approval further adds to Biocon’s portfolio of complex drug products

    Read More
  • Biocon’s arm enters into strategic collaboration agreement with Civica
    7th Mar 2025, 09:36 AM

    The agreement aims to expand access and affordability of Insulin Aspart in the United States

    Read More
  • Biocon’s arm gets USFDA’s nod for Lenalidomide Capsules, Dasatinib Tablets, Rivaroxaban Tablets
    5th Mar 2025, 11:12 AM

    Biocon Pharma received tentative approval of its ANDA for Rivaroxaban Tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.